Chengzhi Co., Ltd. (SHE:000990)
5.28
-0.34 (-6.05%)
Oct 23, 2026, 1:55 PM CST
Chengzhi Revenue
Chengzhi had revenue of 2.27B CNY in the quarter ending September 30, 2026, a decrease of -16.80%. This brings the company's total for the last twelve months to 10.74B, down -6.91% year-over-year. In the year 2025, Chengzhi had annual revenue of 11.03B, down -0.35%. That makes Chengzhi the 5,733rd largest company in the world by revenue and 757th in China.
Revenue (ttm)
10.74B
Revenue Growth
-6.91%
P/S Ratio
0.89
Revenue / Employee
2.41M
Employees
4,462
Market Cap
8.98B
Revenue by Segment
- Clean Energy Industry Segment 8.57B 77.1%
- Chemical New Materials Industry 1.63B 14.7%
- Life Sciences Division 728.33M 6.6%
- Other Industry Segment 188.27M 1.7%
Fiscal year ended Dec 31, 2025 See the full Chengzhi breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.03B | -38.43M | -0.35% |
| Dec 31, 2024 | 11.07B | -1.35B | -10.88% |
| Dec 31, 2023 | 12.42B | 700.11M | 5.97% |
| Jan 1, 2023 | 11.72B | -466.63M | -3.83% |
| Jan 1, 2022 | 12.18B | 2.45B | 25.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pacific Shuanglin Bio-pharmacy | 2.48B |
| Tibet Cheezheng Tibetan Medicine | 2.22B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 2.03B |
| Inner Mongolia Furui Medical Science | 1.64B |
| Shanghai Medicilon | 1.38B |
| Mabwell (Shanghai) Bioscience | 873.99M |
| Chengdu Olymvax Biopharmaceuticals | 759.63M |
| Shanghai OPM Biosciences | 630.86M |